Michael Erickson Sells 5,371 Shares of IDEXX Laboratories (NASDAQ:IDXX) Stock

IDEXX Laboratories, Inc. (NASDAQ:IDXX) EVP Michael Erickson sold 5,371 shares of the business’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $627.38, for a total value of $3,369,657.98. Following the transaction, the executive vice president owned 12,693 shares in the company, valued at approximately $7,963,334.34. This trade represents a 29.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

IDEXX Laboratories Trading Up 0.8%

IDEXX Laboratories stock opened at $635.66 on Friday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23. The stock has a market cap of $50.76 billion, a PE ratio of 48.64, a price-to-earnings-growth ratio of 3.84 and a beta of 1.67. The stock has a 50-day moving average of $677.74 and a two-hundred day moving average of $668.82. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Monday, February 2nd. The company reported $2.92 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.93 by ($0.01). The company had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The business’s revenue was up 14.3% compared to the same quarter last year. During the same quarter last year, the company earned $2.53 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Institutional Trading of IDEXX Laboratories

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. EverSource Wealth Advisors LLC boosted its position in IDEXX Laboratories by 2.5% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 621 shares of the company’s stock worth $397,000 after purchasing an additional 15 shares in the last quarter. STF Management LP lifted its stake in shares of IDEXX Laboratories by 1.3% in the 2nd quarter. STF Management LP now owns 1,240 shares of the company’s stock valued at $665,000 after purchasing an additional 16 shares during the period. Clearstead Trust LLC boosted its holdings in IDEXX Laboratories by 1.1% during the second quarter. Clearstead Trust LLC now owns 1,515 shares of the company’s stock worth $813,000 after buying an additional 16 shares in the last quarter. MassMutual Private Wealth & Trust FSB boosted its holdings in IDEXX Laboratories by 4.4% during the third quarter. MassMutual Private Wealth & Trust FSB now owns 380 shares of the company’s stock worth $243,000 after buying an additional 16 shares in the last quarter. Finally, Harbour Investments Inc. grew its position in IDEXX Laboratories by 13.3% during the fourth quarter. Harbour Investments Inc. now owns 136 shares of the company’s stock valued at $92,000 after buying an additional 16 shares during the period. 87.84% of the stock is owned by institutional investors and hedge funds.

Key IDEXX Laboratories News

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: Analyst support remains a tailwind — multiple firms continue to rate IDXX favorably (Jefferies, BTIG, Barclays among others) and the consensus remains a “Moderate Buy” with a material above‑current price target consensus. That analyst backdrop can support buying interest. Read More.
• Neutral Sentiment: Company fundamentals: IDXX reported a slight EPS miss (by $0.01) for the most recent quarter but beat on revenue (+14% y/y) and provided FY‑2026 EPS guidance of $14.29–$14.80 — guidance is above many near‑term expectations, which is generally constructive for the stock. Read More.
• Neutral Sentiment: Re‑rating narrative: recent commentary (Conestoga/InsiderMonkey, Yahoo syndicated pieces) argues IDXX shares are re‑rating toward historical averages — this is discussion‑driven and could help multiple investors re‑allocate into the name if the argument gains traction. Read More.
• Neutral Sentiment: Comparisons in the sector: valuation/sector pieces (e.g., Zacks comparing SONVY vs IDXX) may influence relative‑value flows but don’t present new company‑specific catalysts. Read More.
• Neutral Sentiment: Short‑interest data posted for February appears to show zero shares / zero days‑to‑cover (likely a reporting anomaly). That suggests no clear short‑squeeze pressure at present but verify with exchange short‑interest releases.
• Negative Sentiment: Insider selling: multiple execs disclosed sizable sales on Feb 17 — Director Sophie Vandebroek sold 1,464 shares (~$628.62 avg) and EVP Michael Erickson sold 5,371 shares (~$627.38 avg). Large insider sales can be read as signal of personal liquidity/positioning and may weigh on near‑term sentiment. Read More. Read More.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Morgan Stanley upped their target price on IDEXX Laboratories from $765.00 to $805.00 and gave the company an “overweight” rating in a research report on Tuesday, November 4th. Barclays cut their price objective on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th. Piper Sandler decreased their target price on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a report on Monday, February 9th. Weiss Ratings lowered IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, January 29th. Finally, Wall Street Zen raised shares of IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 7th. Seven analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $783.33.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.